Evaluation of the do bugs need drugs? Program in British Columbia: Can we curb antibiotic prescribing?

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 22, Issue 1, 2011, Pages 19-24

  McKay, Rachel M ^a   Vrbova, Linda ^b   Fuertes, Elaine ^b   Chong, Mei ^a   David, Samara ^a   Dreher, Kim ^a   Purych, Dale ^c,d   Blondel Hill, Edith ^b,e   Henry, Bonnie ^a,b   Marra, Fawziah ^a,b   Kendall, Perry R W ^f   Patrick, David M ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC Biomedical Laboratories Ltd   (Canada)

^d FRASER HEALTH AUTHORITY   (Canada)

^e Interior Health Authority   (Canada)

^f MINISTRY OF HEALTH   (Canada)

Author keywords

Antibiotics; Community education; Program evaluation; Utilization

Indexed keywords

ANTIBIOTIC AGENT; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CANADA; CHILD; CLINICAL ASSESSMENT; DRUG COST; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; OTITIS MEDIA; PHARYNGITIS; PHYSICIAN; PRESCRIPTION; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 79953249028     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/745090     Document Type: Article

References (28)

1. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992;257:1050-5.
2. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med 2004;10:S122-9.
3. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004;48:3305-11.
4. World Health Organization. Overcoming antimicrobial resistance. 〈http://www.who.int/infectious-disease-report/2000/index.html〉 (Accessed on August 18, 2009).
5. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002;50(Suppl1):1-5. (Pubitemid 34785276)
6. Riedel S, Beekmann S, Heilmann K, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus Pneumoniae. Eur J Clin Microbiol Infect Dis 2007;26:485-90. (Pubitemid 47025039)
7. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005;365:579-87. (Pubitemid 40247914)
8. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8:278-82. (Pubitemid 34266265)
9. Tenover FCP, McGowan JE Jr. Reasons for the emergence of antibiotic resistance. Am J Med Sci 1996;311:9-16.
10. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: Antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother 2007;51:3491-7. (Pubitemid 47519334)
11. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:3646-50.
12. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90. (Pubitemid 46209315)
13. Fishman N. Antimicrobial stewardship. Am J Med 2006;119(Suppl 1):S53-61.
14. Wang EE, Einarson TR, Kellner JD, Conly JM. Antibiotic prescribing for Canadian preschool children: Evidence of overprescribing for viral respiratory infections. Clin Infect Dis 1999;29:155-60. (Pubitemid 29336818)
15. Worrall G, Young B, Knight V. Inappropriate use of antibiotics for acute respiratory tract infections in a rural emergency department. Can J Rural Med 2005;10:86-8.
16. Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: A systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002;7:111-7. (Pubitemid 34984017)
17. Avorn JL, Barrett JF, Davey PG, McEwan SA, O'Brien TF, Levy SB. Antibiotic resistance: Synthesis of recommendations by expert policy groups. World Health Organization, 2001.
18. Ranji SR, Steinman MA, Shojania KG, Gonzales R. Interventions to reduce unnecessary antibiotic prescribing: A systematic review and quantitative analysis. Med Care 2008;46:847-62.
19. Belongia EA, Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ 1998;317:668-71. (Pubitemid 28403500)
20. Ebert SC. Factors contributing to excessive antimicrobial prescribing. Pharmacotherapy 2007;27:126S-30S.
21. Goossens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol 2006;62:373-9.
22. Fuertes E, Henry B, Marra F, Wong H, Patrick DM. Trends in antibiotic utilization in Vancouver with a community education program on antibiotic use. Can J Public Health 2010;101:304-8.
23. Ministry of Health Services. Pharmanet. 〈www.health.gov.bc.ca/ pharmacare/pharmanet/netindex.html 2009〉 (Accessed on December 9, 2009).
24. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology, 2009.
25. Marra F, Patrick DM, Chong M, Bowie WR. Antibiotic use among children in British Columbia, Canada. J Antimicrob Chemother 2006;58:830-9. (Pubitemid 44390961)
26. Blondel-Hill E, Fryters S. Bugs & Drugs. Edmonton: Capital Health, 2006.
27. Gonzales R, Corbett K, Leeman-Castillo B, et al. The "Minimizing Antibiotic Resistance in Colorado" Project: Impact of patient education in improving antibiotic use in private office practices. Health Serv Res 2005;40:101-16.
28. Marra F, Patrick DM, White R, Ng H, Bowie WR, Hutchinson JM. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia. J Antimicrob Chemother 2005;55:95-101. (Pubitemid 40192620)